Joint Research on Exosomes and Their Clinical Application and Commercialisation
First written in FY2019. 7 of 8 entries say "Advanced", first in FY2020. Latest entry: 2026-09-08.
1 other company's latest entry also says "Advanced".
- FY2023-Q2AdvancedAnnual report
「With the acquisition of the new CPC (cell processing center) this time, we will expand the manufacturing site area by more than 10-fold and strengthen our manufacturing capabilities in anticipation of increased future contract orders and the launch of new businesses, including the exosome drug discovery business.」
The acquisition of a new CPC, which will expand the manufacturing site area by more than 10-fold, was decided in anticipation of new businesses, including the exosome drug discovery business. - FY2022AdvancedAnnual report
「April 2022: Developed "CellSource Exosome," an exosome-derived cosmetic ingredient」
In addition to joint research with universities and clinical applications, exosome-related technology advanced to a specific commercialization stage: the development of cosmetic ingredients. - FY2021AdvancedAnnual report
「June 2021: Entered into a joint research agreement with Juntendo University concerning treatment of sequelae of cerebral infarction and Parkinson's disease using exosomes」
Following the chronic obstructive pulmonary disease treatment research with Osaka University, a joint research agreement was entered into with Juntendo University concerning treatment for sequelae of cerebral infarction and Parkinson's disease. - FY2020AdvancedAnnual report
「December 2020: Entered into a joint research agreement with Osaka University concerning treatment for chronic obstructive pulmonary disease using adipose-derived stem cell exosomes and other materials」
A specific research subject, treatment for chronic obstructive pulmonary disease using exosomes and other materials, was added to the joint research with Osaka University. - FY2019First statedAnnual report
「The company plans to promote joint research with other businesses relating to exosomes.」
Exosomes are being considered for expansion into new contract manufacturing and processing services and the drug discovery business.